Lancaster, CA–(business wire) — Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of drug safety and efficacy modeling and simulation software and services, today announced the release of DILIsym by its DILIsym Services (DSS) division. announced that® Version X (DSX) Beta is the latest version of the flagship quantitative systems toxicology (QST) software for predicting and investigating drug-induced liver injury (DILI).
Dr. Paul B. Watkins, Chair of the DILI-sim Initiative’s Scientific Advisory Board, said: DSX represents a major breakthrough in terms of simplifying the use of the software and significantly increasing the speed at which it delivers results. This will enable wider adoption of the software by pharmaceutical companies, regulators and academics. ”
Dr. Brett Howell, President of DILIsym Services, added: This latest release of DSX is the result of a great deal of effort by our software development team, led by our Senior Software Engineer, Corey Berry, and significantly improves the speed and usability of DILIsym forward. ”
DILIsym modeling supports key drug development decisions by predicting the potential DILI risk of new drug candidates. Modeling can also identify the biochemical events leading to her DILI caused by a drug, thereby predicting a specific subgroup of patients at high risk for her DILI from that drug. Information from DILIsym modeling can help guide go/no-go decisions for major drug development projects, avoiding the disastrous financial impact of failed clinical trials or, better yet, helping DILI reach FDA approval. It provides assurance that it is not an insurmountable obstacle. For the past 12 years, the DILIsym Services Division has coordinated his DILI-sim initiative, a public-private partnership that has guided the development of the DILIsym software package.
Major DSX updates include:
Complete software redesign, including command line and graphical interface options, and server/cloud computing capabilities (HPGL)
Four new exemplars in various clinical indications:
PF-04895162 (Genero 2019)
Two new SimCohorts containing variability in susceptibility to liver injury and biomarker-related parameters (ALT and bilirubin)
Contact us to receive your free trial now!
About Simulation Plus
Serving clients worldwide for over 25 years, Simulations Plus is a leading provider of biosimulation marketplaces, providing software and consulting services to support drug discovery, development, research and regulatory submissions. I’m here. We provide solutions that bridge machine learning, physiologically-based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotech and regulatory bodies around the world. For more information, please visit our website at www.simulations-plus.com. Follow us on LinkedIn | twitter | | YouTube.
Environmental, Social and Governance (ESG)
We focus our environmental, social and governance (ESG) efforts where we can have the most positive impact. For more information on our latest initiatives and priorities, please visit his website to view our ESG report.
Safe Harbor Declaration under the Private Securities Litigation Reform Act of 1995 – Other than historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words such as “believe,” “expect,” and “anticipate” mean that these are our best estimates at the time of this writing, but that any expected or anticipated results or events There is no guarantee that it will occur, so actual future results are possible. Very different from those statements. Factors that may cause or contribute to such differences include our ability to maintain a competitive advantage, customer acceptance of new and improved versions of existing software, and the pharmaceutical industry’s general economics, our capabilities, etc. The ability to fund growth, the ability to attract and retain the best technical staff, the ability to identify and complete acquisitions on favorable terms for the company, and a sustainable market. Further information regarding our risk factors is contained in our quarterly and annual reports, which are filed with the US Securities and Exchange Commission.